Top Page
Vor Biopharma
(NASDAQ:VOR)
Vor Biopharma (VOR) vs. SPDR S&P 500 ETF (SPY)
Vor Biopharma Business Overview & Revenue Model
Vor Biopharma Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.69M | 0.00 | -3.49M | -8.96M | 0.00 | 0.00 |
| EBITDA | -1.12B | -117.66M | -114.37M | -83.13M | -67.58M | -42.76M |
| Net Income | -2.45B | -116.91M | -117.86M | -92.09M | -68.90M | -43.34M |
Balance Sheet | ||||||
| Total Assets | 176.24M | 142.89M | 209.83M | 299.37M | 242.59M | 75.91M |
| Cash, Cash Equivalents and Short-Term Investments | 170.46M | 91.93M | 137.18M | 230.25M | 207.47M | 48.54M |
| Total Debt | 3.06M | 31.83M | 35.66M | 38.91M | 18.01M | 18.29M |
| Total Liabilities | 2.40B | 46.23M | 59.10M | 48.76M | 26.33M | 27.64M |
| Stockholders Equity | -2.23B | 96.66M | 150.72M | 250.61M | 216.26M | 48.27M |
Cash Flow | ||||||
| Free Cash Flow | -144.67M | -99.89M | -101.36M | -93.61M | -73.04M | -40.45M |
| Operating Cash Flow | -143.97M | -99.66M | -100.29M | -85.14M | -69.14M | -36.29M |
| Investing Cash Flow | 100.00K | 96.86M | 71.01M | -94.09M | -91.65M | -4.16M |
| Financing Cash Flow | 249.29M | 53.39M | 2.94M | 117.14M | 232.91M | 82.53M |
Vor Biopharma Technical Analysis
Vor Biopharma Risk Analysis
Vor Biopharma Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $152.12M | 7.06 | 19.23% | ― | ― | ― | |
58 Neutral | $268.76M | -1.92 | -37.98% | ― | ― | 14.33% | |
56 Neutral | $498.17M | -2.25 | -70.82% | ― | ― | -21.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $308.06M | ― | ― | ― | ― | -1072.48% | |
47 Neutral | $145.81M | -0.86 | -74.28% | ― | -19.00% | -2.72% | |
42 Neutral | $160.78M | -2.22 | -114.26% | ― | -17.87% | 14.42% |
Vor Biopharma Corporate Events
Vor Biopharma announced that it will present and host one-on-one investor meetings at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026, where it is highlighting telitacicept as a leading dual BAFF/APRIL inhibitor for B cell–mediated autoimmune diseases. The company emphasized that telitacicept already has an established commercial footprint and broad clinical data package in China through partner RemeGen across several autoimmune conditions, a favorable and predictable safety profile observed in about 1,800 clinical trial participants and tens of thousands of treated patients, and robust efficacy signals in generalized myasthenia gravis, while outlining a global development plan that includes a Phase 3 trial in generalized myasthenia gravis with topline data expected in the first half of 2027 and a Phase 3 trial in Sjögren’s disease planned to start in the first half of 2026, supported by approximately $450 million in cash and investments as of December 2025, which the company says provides runway into mid-2028 to fund these key milestones.
The most recent analyst rating on (VOR) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Vor Biopharma stock, see the VOR Stock Forecast page.
On December 31, 2025, Vor Biopharma Inc. entered into a separation agreement with its Chief Development Officer, Dr. Qing Zuraw, following her decision to pursue other opportunities, with her employment ending the same day and severance benefits provided in line with the terms of her 2025 employment agreement and subsequent amendment. The agreement includes a general release of claims, a 12‑month non‑compete, and standard non‑disparagement and confidentiality provisions, and the company expects to engage Dr. Zuraw as a consultant to support the transition during the first quarter of 2026, signaling an effort to maintain continuity in its development operations despite the leadership change.
The most recent analyst rating on (VOR) stock is a Hold with a $13.50 price target. To see the full list of analyst forecasts on Vor Biopharma stock, see the VOR Stock Forecast page.
On December 15, 2025, Vor Bio entered into a securities purchase agreement for a $150 million private placement of 13,876,032 common shares at $10.81 each to a group of institutional and accredited healthcare specialist investors, including RA Capital Management and Forbion, without using a placement agent. The company plans to use the proceeds to fund the clinical development of its lead asset telitacicept, including an ongoing global Phase 3 trial in myasthenia gravis and a planned global Phase 3 trial in primary Sjögren’s disease, and for general corporate purposes, while concurrently granting investors registration rights for resale of the shares and allowing Forbion to appoint one director to Vor Bio’s board. On December 17, 2025, board member Sarah Reed resigned without a dispute, and on December 18, 2025, Vor Bio appointed RA Capital’s Andrew Levin as an independent Class II director and Forbion’s Wouter Joustra as an independent Class III director, moves that deepen the company’s ties with major life sciences investors and bring additional venture and capital markets expertise to its board as it advances late-stage autoimmune programs.
The most recent analyst rating on (VOR) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on Vor Biopharma stock, see the VOR Stock Forecast page.
On December 5, 2025, Vor Biopharma‘s board approved a stock option repricing, reducing the exercise price of certain options to $8.18 per share to align with the market value on that date. This decision aims to retain and motivate employees by making their options more attractive without incurring additional equity or cash costs, impacting approximately 5.2 million shares. The repricing includes options held by key executives, such as CEO Jean-Paul Kress, and involves a retention period until December 5, 2027, or other specified conditions. Additionally, CFO Sandy Mahatme’s restricted stock units were replaced with an option to purchase 1,388,274 shares, with similar repricing terms.
The most recent analyst rating on (VOR) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Vor Biopharma stock, see the VOR Stock Forecast page.
On November 10, 2025, Vor Biopharma Inc. announced an underwriting agreement for a public offering of 10 million shares of common stock at $10 per share, expected to raise approximately $93.7 million. The proceeds will be used to advance clinical development of telitacicept, including a Phase 3 trial for primary Sjögren’s Disease, and support manufacturing and pre-commercialization activities. This financial move aims to sustain the company’s operations and capital expenditures into the second quarter of 2027, potentially strengthening its position in the biotechnology sector.
The most recent analyst rating on (VOR) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Vor Biopharma stock, see the VOR Stock Forecast page.
On November 2, 2025, Vor Biopharma Inc. amended the employment agreement with its Chief Development Officer, Dr. Qing Zuraw, to include additional severance benefits in case of termination without cause or resignation after December 31, 2025. On November 3, 2025, Vor Bio announced the appointment of Dr. Jeremy Sokolove as Chief Medical Officer, bringing extensive experience in rheumatology and autoimmune disease research to the company, which aims to advance its clinical strategy and enhance patient outcomes.
The most recent analyst rating on (VOR) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Vor Biopharma stock, see the VOR Stock Forecast page.
On October 28, 2025, Vor Biopharma Inc. hosted a webcast to present 48-week Phase 3 clinical trial data from China for telitacicept in treating primary Sjögren’s disease. The results indicated significant improvements in disease symptoms and control, with nearly 90% of patients reporting positive outcomes. This development positions telitacicept as a potentially transformative therapy in the autoimmune disease space, enhancing Vor Biopharma’s competitive edge and offering promising implications for stakeholders in terms of market opportunities and patient treatment options.
The most recent analyst rating on (VOR) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on Vor Biopharma stock, see the VOR Stock Forecast page.